



HAL
open science

Implementation of the French primary long-term prophylaxis guidelines: A real-world prospective study of the FranceCoag PUPs cohort

P. Saultier, Y. Guillaume, V. Demiguel, C. Berger, A. Borel-Derlon, S. Claeysens, A. Harroche, C. Oudot, A. Rafowicz, M. Trossaërt, et al.

► To cite this version:

P. Saultier, Y. Guillaume, V. Demiguel, C. Berger, A. Borel-Derlon, et al.. Implementation of the French primary long-term prophylaxis guidelines: A real-world prospective study of the FranceCoag PUPs cohort. 11. Annual Congress of the European Association for Haemophilia and Allied Disorders 2018, The European Association for Haemophilia and Allied Disorders (EAHAD). Bruxelles, BEL., Feb 2018, Madrid, Spain. pp.1, 10.1111/hae.13392 . hal-02735662

HAL Id: hal-02735662

<https://hal.inrae.fr/hal-02735662v1>

Submitted on 2 Jun 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

ABSTRACTS

ORAL PRESENTATIONS

OR01 | Implementation of the French primary long-term prophylaxis guidelines: A real-world prospective study of the FranceCoag PUPs cohort

P. Saultier^{1,2,*}; Y. Guillaume¹; V. Demiguel³; C. Berger⁴; A. Borel-Derlon⁵; S. Claeysens⁶; A. Harroche⁷; C. Oudot⁸; A. Rafowicz⁹; M. Trossaert¹⁰; B. Wibaut¹¹; M. Boucekine¹²; K. Baumstarck¹²; S. Meunier¹³; T. Calvez¹⁴; H. Chambost^{1,2}; on behalf of FranceCoag PUPs / CoMETH Prophylaxis Study Group

¹CHU Timone Enfants, Department of pediatric hematology and oncology, APHM, Marseille, France; ²NORT, Aix Marseille Univ, INSERM, INRA, Marseille, France; ³Santé Publique France, French national public health agency, Saint-Maurice, France; ⁴Hematology and Oncology Pediatric Unit, Saint-Etienne University Hospital, Saint Etienne, France; ⁵Center for bleeding disorders, La Côte de Nacre University Hospital, Caen, France; ⁶Center for bleeding disorders, Purpan University Hospital, Toulouse, France; ⁷Necker University Hospital, Center for bleeding disorders, Assistance Publique - Hôpitaux de Paris, Paris, France; ⁸Hematology and Oncology Pediatric Unit, Limoges University Hospital, Limoges, France; ⁹Bicêtre University Hospital, Center for bleeding disorders, Assistance Publique - Hôpitaux de Paris, Le Kremlin Bicêtre, France; ¹⁰Center for bleeding disorders, Nantes University Hospital, Nantes, France; ¹¹Center for bleeding disorders, Lille 2 University Hospital, Lille, France; ¹²EA 3279, Self-perceived Health Assessment Research Unit, School of Medicine, Aix-Marseille Univ, Marseille, France; ¹³Lyon University Hospital, Center for bleeding disorders, HCL, Lyon, France; ¹⁴Institut Pierre Louis d'Épidémiologie et de Santé publique (IPLESP UMRS 1136), Sorbonne Universités, UPMC Univ Paris 06, Inserm, Paris, France

Introduction: Primary long-term prophylaxis (LTP) efficiently prevents arthropathy in children with severe hemophilia. In early 2000s, the French group of hemophilia treaters (CoMETH) published their first LTP guidelines. Several issues may impair the actual LTP use in young patients. However, real-world evaluations of the implementation of such guidelines are scarce. This study aimed at prospectively analyzing the LTP guidelines implementation in France and at identifying factors modulating the LTP initiation.

Methods: The study group consisted of 395 boys from the FranceCoag PUPs cohort. All included patients had severe hemophilia A or B (FVIII/FIX <1%) and were born in 2000-2009 (i.e. after the French LTP guidelines dissemination). Sociodemographic, clinical, biological, genetic, and therapeutic data were prospectively recorded during medical visits in the hemophilia treatment center (HTC). The study group was compared to a historical group of 44 registered boys with severe hemophilia born in 1996 (retrospective data collection).

Results: In the study group, the median age at first joint bleed was 1.9 years (IQR 1.1-3.0). The cumulative incidence of primary LTP use according to age was dramatically higher in the study group compared to the historical group (e.g. cumulative incidence of LTP use 59.2% versus 8.5% at three years of age, respectively). The prevalence of

ineligibility to the guidelines, delay or absence of LTP initiation, anticipated LTP initiation, and timely LTP initiation according to guidelines was 20.8%, 9.9%, 38.5% and 30.9%, respectively. A multivariate analysis showed that two factors were significantly associated with anticipated or timely *versus* delayed or absent LTP initiation: the year of birth (OR 1.2 per each additional year, 95% CI 1.1-1.3, $P < .001$) and the HTC location (OR 6.4, 95% CI 1.4-29.2, $P = .02$ and OR 6.2, 95% CI 2.0-19.4, $P = .002$ for Northwest and Southeast part of France, respectively).

Discussion/Conclusion: This analysis provides pivotal data to evaluate the adherence to early LTP guidelines and to identify barriers for their implementation. CoMETH guidelines dissemination was associated with a dramatic increase in early LTP use. The study highlights the capacity of FranceCoag device to assess critical variables and evaluate therapeutic practice in one of the largest national PUPs cohort worldwide.

Disclosure of interest: None declared.

OR02 | Within-patient comparison of treatment patterns before and after switching to rFVIIIc: A report from the UK national haemophilia database

M. Scott^{1,*}; X. Hua²; P. W. Collins³; C. R. M. Hay¹; on behalf of UKHCDO

¹Clinical Haematology, Manchester Royal Infirmary, Manchester, UK; ²UK National Haemophilia Database, Manchester, UK; ³School of Medicine, Cardiff University, University Hospital of Wales, Cardiff, UK

Introduction: Extended half-life (EHL) FVIII products may permit a reduction of infusion frequency (IF) and clotting factor consumption (CFC) whilst improving bleeding outcomes in haemophilia A (HA). Direct comparisons with standard rFVIII do not exist. We compared IF and CFC in patients using FVIII prophylaxis before and after switching to rFVIIIc using data from the UK National Haemophilia Database.

Methods: rFVIIIc was introduced in the UK from September 2016 using a restricted NHS England protocol. This assumed effective FVIII prophylaxis could be provided using at least one fewer infusion/wk of rFVIIIc than previously required using rFVIII. All UK patients who used rFVIIIc 01/09/16-30/06/2017 were identified. Patients with ≥ 4 -weeks compliant post-switch Haemtrack (HT) home-therapy diary data were analysed. Individual IF and weekly